Fig. 7
From: Exploring Liraglutide’s mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway
Liraglutide inhibited HG-induced ferroptosis via Fsp1-CoQ10. (A) The cell viability of HK-2 cells (n = 6, **p < 0.01 vs. HG group, #p < 0.05 vs. HG + iFsp1 group). (B–C) The fluorescence absorption spectrum of BODIPY 581/591 C11 (scale bar = 100 μm, n = 3, **p < 0.01 vs. HG group, ##p < 0.01 vs. HG + iFsp1 group). (D) The cell viability of HK-2 cells (n = 6, **p < 0.01 vs. HG + LIRA group). (E–F) The fluorescence absorption spectrum of BODIPY 581/591 C11 (scale bar = 100 μm, n = 3, **p < 0.01 vs. HG + LIRA group). (G) Flow cytometry results of BODIPY 581/591 C11 probe. (H) The immunofluorescence double label staining of Fsp1 and 4-HNE (scale bar = 50 μm, n = 3). (I–J) The expression and statistics of GPX-4 and Fsp1 proteins (n = 3, **p < 0.01 vs. HG + LIRA group). (K–L) The ratio of NAD+/NADH and CoQ10 (H2)/CoQ10 (n = 4, *p < 0.05 vs. HG + LIRA group). The results are presented as the mean ± SEM.
